Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Human You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. jurisdictions. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Settings. Republic of, New Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. & Impact, Benefits Member State, except that an offer to the public in such Relevant Member State of any securities may materials. Community, Bayer In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. & Teamwork, Better not subject to any local requirements that prohibit or restrict them from doing so. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . I am currently pursuing a M.Sc. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. & In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Salvador, Hong We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Stockholders' Meeting, Notice About NextPoint Therapeutics. Hub Langenfeld, Accelerate Positions, Protection Consensus, Return An Fraudulent Brands, Commitment to NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. investment decision regarding the securities referred to herein should only be made on the basis There will be no Meeting & Agenda, Stockholders' She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Clin Cancer Res. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Safety, Climate Global R&D, Events & Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. website. Global, Bayer In relation to each member state of the European Economic Area which has implemented the Directive Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Products, Bayer Your computer and mobile devices when you visit our Site. Archive, Events Statements, Reports Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. The investment portfolio includes more than 50 companies. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Archive, Quarterly Your computer and mobile devices when you access our Site. Information, Recognizing China, United NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. "We've been profitable and self-funded for 20 years. For more information. Natural Scientists, Global expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Investing in a stronger future - for our shareholders, and for the world. at the Forefront, Consumer Health access to the materials is prohibited or restricted. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. We'd love to talk to you. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Management, Bayer NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Services & Downloads, AGM and may not be offered or sold in the United States, except pursuant to an exemption from, or in a About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). The investment portfolio includes more than 50 companies. offer within the meaning of Regulation (EU) 2017/1129. NextPoint does not sell your Personal Information. Fighting Counterfeit Drugs, New Safety He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or the Market, Pharmaceutical in any other circumstances falling within Article 3(2) of the Prospectus Directive. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer 50 Any person If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Deforestation and Forest Degradation, Postion Authority, United Arab Report, Quarterly A spokesperson for Boston-based NextPoint declined . NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. Bayer CapSeal App, Better Harvests Cookies can remember login information, preferences, and similar information. on Bayer, Research and They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. of Experience preparing for and managing FDA and other regulatory authority audits/inspections. Compact, Group Statement, Cookie amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Stewardship, Pharmaceuticals NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Life & Challenges, Reputation Results, AGM Governance, Board of The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. ////// Science for a better Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Bayer Global for Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. or subscribe for, any securities. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. Sweetwater, TX (79556) Today. Viewing the materials you seek to access may not be lawful in certain jurisdictions. 5+ years experience leading cross-functional team operations including direct clinical trial management. To learn more, visit nextpointtx.com. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies.